Cytokinetics Company Profile (NASDAQ:CYTK)

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its lead drug candidate from its skeletal muscle contractility program, tirasemtiv, is a skeletal muscle troponin activator. The Company is developing CK-2127107, a skeletal muscle troponin activator. The Company has conducted approximately five Phase I clinical trials of CK-2127107. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is a cardiac muscle myosin activator. COSMIC-HF is a Phase II, double-blind, randomized, placebo-controlled, multicenter, clinical trial designed to assess the pharmacokinetics and tolerability of omecamtiv mecarbil dosed orally in patients with heart failure and left ventricular systolic dysfunction.

Industry, Sector and Symbol:

• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Exchange: NASDAQ
• Symbol: CYTK
• CUSIP:

Key Metrics:

• Previous Close: $9.18
• 50 Day Moving Average: $10.39
• 200 Day Moving Average: $9.06
• 52-Week Range: $6.00 - $13.18
• Trailing P/E Ratio: N/A
• Foreward P/E Ratio: -5.85
• P/E Growth: -0.45
• Market Cap: $364.47M
• Outstanding Shares: 39,703,000
• Beta: 1.29

Profitability:

• Net Margins: -132.01%
• Return on Equity: -69.51%
• Return on Assets: -38.59%

Debt:

• Debt-to-Equity Ratio: 0.61%
• Current Ratio: 3.68%
• Quick Ratio: 3.68%

Additional Links:

• Visit Cytokinetics' Official Website
• View CYTK on Google Finance
• View CYTK on Yahoo Finance
• View CYTK's Company Profile on Reuters
• Search for Cytokinetics Inc. on Google

Companies Related to Cytokinetics:

• Vanda Pharmaceuticals (NASDAQ:VNDA)
• Albany Molecular Research (NASDAQ:AMRI)
• Corcept Therapeutics (NASDAQ:CORT)
• Quality Systems (NASDAQ:QSII)
• Anika Therapeutics (NASDAQ:ANIK)
• Inovio Pharmaceuticals (NASDAQ:INO)
• LHC Group (NASDAQ:LHCG)
• Quidel Corp. (NASDAQ:QDEL)
• Adeptus Health (NYSE:ADPT)
• Civitas Solutions (NYSE:CIVI)

Earnings

Earnings History for Cytokinetics (NASDAQ:CYTK)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call	Details
10/27/2016
7/28/2016	Q2	($0.28)	($0.29)			View	Listen
4/28/2016	Q1	($0.37)	($0.31)			View	Listen
2/16/2016	Q415	($0.32)	($0.24)	$10.49 million	$9.80 million	View	Listen
10/29/2015	Q315	($0.30)	($0.23)	$11.24 million	$7.90 million	View	Listen
4/30/2015	Q1	($0.12)	($0.23)	$10.10 million	$4.40 million	View	Listen
2/12/2015	Q4	($0.17)	$0.23	$10.80 million	$21.80 million	View	Listen
10/30/2014	Q3	($0.27)	($0.16)			View	Listen
7/30/2014	Q2	($0.32)	($0.23)	$7.01 million	$7.80 million	View	Listen
5/6/2014	Q1	($0.34)	($0.27)	$7.69 million	$8.00 million	View	Listen
2/6/2014	Q4	($0.08)	$0.21	$19.14 million	$24.30 million	View	Listen

(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cytokinetics (NASDAQ:CYTK)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	1	($0.33)	($0.33)	($0.33)
Q2 2016	1	($0.39)	($0.39)	($0.39)
Q3 2016	1	($0.42)	($0.42)	($0.42)
Q4 2016	1	($0.44)	($0.44)	($0.44)

(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cytokinetics (NASDAQ:CYTK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cytokinetics (NASDAQ:CYTK)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Details
8/31/2015	L Patrick Gage	Director	Buy	1,000	$6.95	$6,950.00
8/20/2015	L Patrick Gage	Director	Buy	10,000	$6.55	$65,500.00
5/6/2015	L Patrick Gage	Director	Buy	10,000	$5.71	$57,100.00
3/11/2015	Andrew A Wolff	CMO	Sell	21,875	$7.80	$170,625.00
12/30/2014	Fady Ibraham Malik	SVP	Sell	21,630	$6.73	$145,569.90
5/9/2014	L Patrick Gage	Director	Buy	10,850	$4.09	$44,376.50
2/25/2014	Eastern Capital Ltd	major shareholder	Buy	500,000	$8.00	$4,000,000.00

(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cytokinetics (NASDAQ:CYTK)

Date	Headline
	Cytokinetics (CYTK) Announces Early HSR Act Termination in ... - StreetInsider.com (NASDAQ:CYTK) www.streetinsider.com - September 29 at 9:32 AM
	Cytokinetics Announces Early Termination of Hart-Scott-Rodino Waiting Period for Expanded Collaboration With Astellas (NASDAQ:CYTK) www.publicnow.com - September 29 at 9:32 AM
	Noteworthy Friday Option Activity: CNP, CAT, CYTK - Nasdaq (NASDAQ:CYTK) www.nasdaq.com - September 24 at 9:13 AM
	Noteworthy Friday Option Activity: CNP, CAT, CYTK (NASDAQ:CYTK) www.stockoptionschannel.com - September 23 at 4:20 PM
	Cytokinetics Inc. (CYTK) Stock Price Up 3.3% - NewsDen (NASDAQ:CYTK) newsden.net - September 22 at 4:40 PM
	Cytokinetics (CYTK) Presents Additional COSMIC-HF Data; Possible Improvement in Symptoms Noted - StreetInsider.com (NASDAQ:CYTK) www.streetinsider.com - September 19 at 3:25 PM
	Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA Annual Scientific Meeting (NASDAQ:CYTK) www.4-traders.com - September 19 at 9:12 AM
	CYTOKINETICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:CYTK) biz.yahoo.com - September 19 at 9:12 AM
	Cytokinetics (NASDAQ:CYTK) Sellers Covered 0.13% of Their Shorts - Post News (NASDAQ:CYTK) www.kentuckypostnews.com - September 17 at 4:26 PM
	Cytokinetics (CYTK) Says Additional Results From COSMIC-HF to Be Presented at HFSA - StreetInsider.com (NASDAQ:CYTK) www.streetinsider.com - September 10 at 9:08 AM
	Cytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the HFSA Annual Scientific Meeting (NASDAQ:CYTK) finance.yahoo.com - September 9 at 4:24 PM
	Form 8-K CYTOKINETICS INC For: Sep 08 - StreetInsider.com (NASDAQ:CYTK) www.streetinsider.com - September 8 at 8:20 AM
	Cytokinetics Announces Next-Generation Fast Skeletal Muscle Activator Entering IND-Enabling Studies (NASDAQ:CYTK) www.publicnow.com - September 8 at 8:20 AM
	ETF’s with exposure to Cytokinetics, Inc. : September 6, 2016 (NASDAQ:CYTK) www.capitalcube.com - September 6 at 4:26 PM
	Expert Analysts Sentiments for: Cytokinetics, Incorporated (NASDAQ:CYTK) , Methode Electronics, Inc. (NYSE:MEI) - Wall Street Times (press release) (NASDAQ:CYTK) www.wallstreetnews24.com - September 3 at 4:15 PM
	Most Volatile Biotech Stocks- Array BioPharma (NASDAQ:ARRY), Cytokinetics (NASDAQ:CYTK) - Seneca Globe (NASDAQ:CYTK) www.senecaglobe.com - September 3 at 4:15 PM
	Here's Why You Should Buy Cytokinetics, Inc. (CYTK) As Amgen, Inc. (AMGN) Enters Phase 3 Study - TCC (NASDAQ:CYTK) www.thecountrycaller.com - September 3 at 4:15 PM
	Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development (NASDAQ:CYTK) www.biomedreports.com - September 2 at 4:21 PM
	Cytokinetics, Inc. breached its 50 day moving average in a Bearish Manner : CYTK-US : September 2, 2016 (NASDAQ:CYTK) www.capitalcube.com - September 2 at 9:23 AM
	Noteworthy Thursday Option Activity: SGMS, CYTK, GCO (NASDAQ:CYTK) www.nasdaq.com - September 1 at 4:27 PM
	Cytokinetics Heart Drug Moves to Late-Stage Development (NASDAQ:CYTK) ih.advfn.com - September 1 at 4:27 PM
	Will Cytokinetics (CYTK) Stock Be Helped by Cardiovascular Drug Advancement? (NASDAQ:CYTK) www.thestreet.com - September 1 at 4:27 PM
	CYTOKINETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements a (NASDAQ:CYTK) biz.yahoo.com - September 1 at 4:27 PM
	8:33 am Cytokinetics to advance omecamtiv mecarbil to Phase 3 clinical trial; Amgen (AMGN (NASDAQ:CYTK) finance.yahoo.com - September 1 at 9:44 AM
	Cytokinetics and Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development (NASDAQ:CYTK) www.publicnow.com - September 1 at 9:44 AM
	Why You Shouldn't Bet Against Cytokinetics (CYTK) Stock (NASDAQ:CYTK) finance.yahoo.com - August 30 at 4:33 PM
	JNP Will Bleed On Failed Trial, CERU Crashes, CYTK Progresses With VITALITY (NASDAQ:CYTK) www.rttnews.com - August 18 at 4:35 PM
	Cytokinetics (CYTK) Announces Completion of VITALITY-ALS Patient Enrollment (NASDAQ:CYTK) www.streetinsider.com - August 18 at 4:35 PM
	Cytokinetics (CYTK) Announces Completion of VITALITY-ALS Patient Enrollment - StreetInsider.com (NASDAQ:CYTK) www.streetinsider.com - August 18 at 9:13 AM
	CYTOKINETICS INC Files SEC form 8-K, Other Events (NASDAQ:CYTK) biz.yahoo.com - August 17 at 8:50 AM
	Cytokinetics Completes Enrollment in VITALITY-ALS, Phase 3 Clinical Trial of Tirasemtiv in Patients With ALS (NASDAQ:CYTK) www.publicnow.com - August 17 at 8:50 AM
	CYTOKINETICS INC Financials (NASDAQ:CYTK) finance.yahoo.com - August 12 at 4:34 PM
	ETF’s with exposure to Cytokinetics, Inc. : August 11, 2016 (NASDAQ:CYTK) www.capitalcube.com - August 11 at 4:39 PM
	Cytokinetics, Inc. :CYTK-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:CYTK) www.capitalcube.com - August 10 at 4:39 PM
	CYTOKINETICS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:CYTK) biz.yahoo.com - August 4 at 10:16 PM
	These Biotech’s are Due for a Run (NASDAQ:CYTK) www.ssuchronicle.com - August 4 at 4:47 PM
	Cytokinetics (CYTK) Shares March Higher, Can It Continue? (NASDAQ:CYTK) finance.yahoo.com - August 4 at 4:47 PM
	JMP Securities Bullish on Cytokinetics, Inc. (CYTK) Following 2Q Update; Sees Key Catalysts on Track - Smarter Analyst (NASDAQ:CYTK) www.smarteranalyst.com - August 2 at 9:20 AM
	Stocks To Watch: Intrexon Corporation (XON), Cytokinetics, Incorporated (CYTK), Alder Biopharmaceuticals Inc. (ALDR) - iStreetWire (NASDAQ:CYTK) istreetwire.com - August 1 at 4:29 PM
	Cytokinetics : reports 2Q loss (NASDAQ:CYTK) www.4-traders.com - July 29 at 9:54 PM
	Cytokinetics (CYTK), Astellas Pharma Expand Colaboration into ALS (NASDAQ:CYTK) www.streetinsider.com - July 29 at 9:54 PM
	Biotech Roundup: Gilead Slump, Celgene Goes Trump, Hemo Data & More - Xconomy (NASDAQ:CYTK) www.xconomy.com - July 29 at 4:37 PM
	Needham reiterated Cytokinetics Inc (NASDAQ:CYTK) as 'Buy' With 17 PT - FTSE News (NASDAQ:CYTK) www.ftsenews.co.uk - July 29 at 4:37 PM
	Cytokinetics's (CYTK) CEO Robert Blum on Q2 2016 Results - Earnings Call Transcript - Seeking Alpha (NASDAQ:CYTK) seekingalpha.com - July 29 at 8:24 AM
	Cytokinetics, Inc. Reports Second Quarter 2016 Financial Results ... - GlobeNewswire (press release) (NASDAQ:CYTK) globenewswire.com - July 29 at 8:24 AM
	Cytokineti cs(CYTK) Notches New Milestone with Expanded Astellas Partnership - Roth Capital (NASDAQ:CYTK) www.streetinsider.com - July 28 at 5:36 PM
	Cytokinetics, Inc. Reports Second Quarter 2016 Financial Results (NASDAQ:CYTK) globenewswire.com - July 28 at 5:36 PM
	Cytokinetics reports 2Q loss (NASDAQ:CYTK) sg.finance.yahoo.com - July 28 at 5:21 PM
	Q2 2016 Cytokinetics Inc Earnings Release - 4:00 pm ET (NASDAQ:CYTK) biz.yahoo.com - July 28 at 7:07 AM
	Cytokinetics and Astellas Announce Option Right for Tirasemtiv and Expansion of Global Collaboration for CK ... - GlobeNewswire (press release) (NASDAQ:CYTK) globenewswire.com - July 27 at 4:40 PM

Social

Cytokinetics (NASDAQ:CYTK) Chart for Saturday, October, 1, 2016